Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
NCT: NCT03510208 · RECRUITING
Brief Summary
The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better distinguish tumor cells from normal brain tissue and identify small tumors that cannot be seen using current imaging methods.
Frequently Asked Questions
What is Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery?
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery is a clinical trial registered under NCT03510208. Current status: RECRUITING.
What is the status of NCT03510208?
The current status of NCT03510208 (Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery) is: RECRUITING.
When did Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery start?
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery started on 2018-05-16.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.